Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings

Published:2020-09 Issue: Volume:136 Page:159-168
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Castañon Eduardo,Sanchez-Arraez Alvaro,Alvarez-Manceñido Felipe,Jimenez-Fonseca Paula,Carmona-Bayonas Alberto^ORCID

Funder

AstraZeneca

Roche

Ipsen

Novartis

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference41 articles.

1. Design considerations for early-phase clinical trials of immune-oncology agents;Wages;J Immunother Cancer,2018

2. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria;Wolchok;Clin Canc Res,2009

3. Methods for accommodating nonproportional hazards in clinical trials: ready for the primary analysis?;Freidlin;J Clin Oncol,2019

4. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1;Champiat;Clin Canc Res,2017

5. Power and sample size calculation for log-rank test with a time lag in treatment effect;Zhang;Stat Med,2009

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Group sequential methods based on supremum logrank statistics under proportional and nonproportional hazards;Statistical Methods in Medical Research;2024-06-05

2. Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?;British Journal of Cancer;2024-01-08

3. Randomized controlled trials and alternative study designs in surgical oncology;European Journal of Surgical Oncology;2023-08

4. New late‐emphasis and combination tests based on infimum and supremum logrank statistics with application in oncology trials;Statistics in Medicine;2023-03-31

5. Multi-state survival models with treatment effects and biomarkers: Simulations for study design assessment;Cancer Epidemiology;2022-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3